Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 May 2017 17:33

RNS Number : 5192E
Verona Pharma PLC
08 May 2017
 

 

 

 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: 

Verona Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to thenotification obligation: 

Growth Equity Opportunities IV, LLC

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

May 2, 2017

6. Date on which issuer notified:

May 5, 2017

7. Threshold(s) that is/are crossed orreached: 

8% to 9% change at direct interest level

     
 

 

8. Notified details:

A: Voting rights attached to shares 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights 

Direct

Direct 

Indirect 

Direct

Indirect

Ordinary Shares

 

GB00B06GSH43

4,424,065

4,424,065

4,424,065

4,424,065

 

4.47%

 

 

US9250501064

 

 

5,333,328

5,333,328

 

5.39%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate 

Exercise/Conversion Period 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instrument

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date 

Exercise/Conversion period 

Number of voting rights instrument refers to

 

% of voting rights 

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,757,393

9.86%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: 

 

Growth Equity Opportunities IV, LLC is a limited liability company formed in the State of Delaware, United States

New Enterprise Associates 15, L.P., a limited partnership formed in the State of Delaware, is its sole member

NEA Partners 15, L.P., a limited partnership formed in the State of Delaware, is its general partner

NEA 15 GP, LLC, a limited liability company formed in the State of Delaware, is its general partner

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will ceaseto hold:

 

12. Date on which proxy holder will cease to holdvoting rights:

 

 

13. Additional information:

Figures are based on a total number of 99,014,164 Ordinary Shares outstanding, as per the Company's Announcement of May 2, 2017.

14. Contact name:

Louis Citron, New Enterprise Associates

15. Contact telephone number:

+1 (410) 842-4000

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUGUBPAUPMGQR
Date   Source Headline
4th Oct 201312:06 pmPRNPlacing of shares
30th Sep 20137:00 amPRNHalf-yearly Report
23rd Sep 20137:00 amPRNNotice of Results
10th Sep 20137:00 amPRNClinical data presented at ERS
5th Sep 20137:01 amPRNPresentations at ERS
5th Sep 20137:00 amPRNAppointment of Richard Bungay as CFO
29th Jul 201310:13 amPRNGrant of Options
25th Jul 20131:23 pmPRNDirector Shareholding
24th Jul 20135:58 pmPRNHolding(s) in Company
23rd Jul 201312:45 pmPRNDirector Shareholding
24th Jun 20137:00 amPRNFirst patient dosed in clinical trial for VRP700
3rd Jun 20134:46 pmPRNResult of AGM
21st May 20134:00 pmPRNATS Tuesday Presentation
20th May 20137:00 amPRNATS Sunday Poster Presentations
16th May 20137:00 amPRNPresentations at ATS Conference
9th May 20138:05 amPRNPosting of Annual Report and AGM Notice
29th Apr 20137:00 amPRNNew Clinical and Scientific Advisory Board Announced
26th Apr 201310:17 amPRNDirector/PDMR Shareholding
15th Apr 20133:01 pmPRNGrant of Options
10th Apr 20133:07 pmPRNDirector's Dealing
10th Apr 201310:23 amPRNDirector Dealings
10th Apr 20137:00 amPRNFinal Results
19th Mar 20131:56 pmPRNHolding(s) in Company
5th Mar 20137:00 amPRNRPL554 demonstrates airway anti-inflammatory activity
28th Feb 20137:00 amPRNTotal Voting Rights
21st Feb 20132:35 pmPRNHolding(s) in Company
18th Feb 20132:53 pmPRNResult of General Meeting
31st Jan 201310:54 amPRNPlacing and Equity Finance Facility
24th Jan 20132:09 pmPRNNotice of Interest
18th Jan 201310:18 amPRNHolding(s) in Company
4th Jan 20132:59 pmPRNStatement Regarding Share Price Movement
12th Nov 201211:38 amPRNNotice of Interest
15th Oct 20122:01 pmPRNDirector Shareholding
12th Oct 20129:00 amPRNRPL554 Phase I/IIa data presented at ISAF 2012
26th Sep 20129:00 amPRNInvestor Presentation
17th Sep 201210:44 amPRNNew Option Scheme and Grant of Options
14th Sep 20127:00 amPRNHalf-yearly Report
6th Sep 20127:00 amPRNNotice of Interim Results
4th Sep 20127:30 amPRNVerona Pharma: RPL554 COPD Data Presented at ERS
3rd Sep 20129:30 amPRNNotice of Interest
28th Aug 20127:00 amPRNUS Patent Granted for Verona Pharma's RPL554
9th Jul 20127:00 amPRNVerona Pharma Investigates Anti-inflammatory - RPL554
1st Jun 20126:14 pmPRNResult of AGM
1st Jun 201211:30 amPRNCEO's Statement to Annual General Meeting
8th May 20124:56 pmPRNPosting of Annual Report
1st May 20127:00 amPRNVerona Pharma appoints new CEO
5th Apr 20127:00 amPRNVerona Pharma - Preliminary Unaudited Results
9th Mar 20127:00 amPRNVerona Pharma â€" First UK RPL554 anti-inflammatory trial
31st Jan 20127:00 amPRNTotal Voting Rights
16th Jan 201212:19 pmPRNNotification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.